Table 4.
Vaccination against COVID-19 in SOT.
| Vaccine |
Efficacy |
Adverse effects |
|||||
|---|---|---|---|---|---|---|---|
| SOT | Patients (n) | Doses | Type | Overall | LT | Local | Systemic |
| Boyarsky et al, 2021 | 658 [LT: 129 (20%)] | 2 | BNT162b2: 51%; mRNA-1273: 40% | D1: 15%; D2: 54% | D1: 32%; D2: 80% | NA | 10 (17%) |
| Marion et al, 2021 | 950 [367 received 2 doses and tested (LT: 58 -16%)] | 1 dose: 376; 2 doses: 576 | BNT162b2 (Pfizer-BioNTech): 942 | D1: 6%; D2: 34% (out of 367) | D2: 50% | NA | 1 LT with paresthesia |
| Ou et al, 2021 | 741 [LT:140(19%)] | BNT162b2: 54% mRNA-1273: 46% | NR | D1: 78% D2: 85% Most common: pain at the injection site | D1 49% D2 69% Most common: fatigue and headache | ||
| Kamar et al, 2021 | 101 LT:12(12%) | BNT162b2:100% | D1: 4%; D2: 40% D3: 68% | NA | NA | ||
| LT recipients | |||||||
| Rabinowich et al, 2021 | 117 | 2 doses | BNT162b2 | D2: 48% (vs. 100% in control group) | D1: 60% D2: 53% | 20% | |
Data expressed as n (%). D1: after first dose; D2: after second dose; D3: after third dose; LT: liver transplant; NA: not available; SOT: Solid-organ transplant.